ReVision Optics Inc. finished the first stage of a clinical trial for its Vue+ lens eye-implant, only to file for an expansion with the Food & Drug Administration.
The Lake Forest, Calif.-based developer of implantable optics plans to evaluate 400 subjects in a three-year trial for its Vue+ device, formerly called the PresbyLens. The company designed the implantable lens to treat presbyopia, the common age-related loss of the ability to focus one’s eyes for near vision. More than 73 million people in the U.S. are presbyopic, according to the company.
ReVision’s Vue+ is a microlens similar to a contact lens that is inserted just beneath the surface of the eye. It is made from a proprietary hydrogel similar in nature to the natural cornea, according to the company. The lens augments corneal curvature to improve near, or reading, vision and decreasing the need for reading glasses.
